Leo J Trevino328 Richfield Ave, Battle Creek, MI 49014

7141235, Nov 28, 2006

Aug 28, 2001

09/941395

Leo A. Trevino - San Diego CA, US
Ernest George Schutt - San Diego CA, US
David H. Klein - Carlsbad CA, US
Thomas E. Tarara - San Diego CA, US
Jeffry G. Weers - San Diego CA, US
Alexey Kabalnov - San Diego CA, US

Imcor Pharmaceutical Co. - San Diego CA

A61B 8/00

424 952, 424 95, 424 951, 600441, 600458

A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.

5798091, Aug 25, 1998

Feb 28, 1995

8/395680

Leo A. Trevino - San Diego CA
Ernest George Schutt - San Diego CA
David H. Klein - Carlsbad CA
Thomas E. Tarara - San Diego CA
Jeffry G. Weers - San Diego CA
Alexey Kabalnov - San Diego CA

Alliance Pharmaceutical Corp. - San Diego CA

A61B 813

424 952

A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.

5874481, Feb 23, 1999

Jun 7, 1995

8/483468

Jeffry G. Weers - San Diego CA
Luis A. Dellamary - San Marcos CA
Thomas E. Tarara - San Diego CA
Leo A. Trevino - San Diego CA
Helen M. Ranney - La Jolla CA

Alliance Pharmaceutical Corp. - San Diego CA

A61K 3102
A61K 31045

514761

A thermodynamically stable molecular solution providing enhanced bioavailability for lipophilic pharmaceutical agents, comprising a liquid carrier comprising one or more physiologically acceptable lipophilic fluorochemicals, and a pharmaceutically effective amount of at least one lipophilic pharmaceutical agent in said liquid carrier to form a thermodynamically stable molecular solution, optionally also including a co-solvent for facilitating solubilization of the pharmaceutical agent. Methods of making and using the molecular solution are also disclosed.

6280705, Aug 28, 2001

Jan 26, 1998

9/013357

Leo A. Trevino - San Diego CA
Ernest George Schutt - San Diego CA
David H. Klein - Carlsbad CA
Thomas E. Tarara - San Diego CA
Jeffry G. Weers - San Diego CA
Alexey Kabalnov - San Diego CA

Alliance Pharmaceutical Corp. - San Diego CA

A61B 813

424 951

A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.

5733526, Mar 31, 1998

Dec 14, 1995

8/572859

Leo A. Trevino - San Diego CA
Jean G. Riess - Falicon, FR
Luis A. Dellamary - San Marcos CA
Marie-Pierre Krafft - Nice, FR
Thomas E. Tarara - San Diego CA

Alliance Pharmaceutical Corp. - San Diego CA

A61K 4904
A61K 3103

424 952

Novel hydrocarbon oil/fluorochemical preparations and methods for their use are provided. The preparations, which preferably comprise a fluorophilic dispersing agent, may be in the form of hydrocarbon oil-in-fluorochemical dispersions or in the form of a multiple emulsion comprising a polar liquid continuous phase and are particularly useful for administering bioactive agents. In particular the preparations of the present invention may be used to control the bioavailability and improve the efficacy of lipophilic bioactive agents having limited solubility in an aqueous physiological environment.

5667809, Sep 16, 1997

Jun 7, 1995

8/482176

Leo A. Trevino - San Diego CA
Luis A. Dellamary - San Marcos CA
Thomas E. Tarara - San Diego CA
Jeffry G. Weers - San Diego CA
Helen M. Ranney - La Jolla CA

Alliance Pharmaceutical Corp. - San Diego CA

A61K 950
A61K 948
A61F 202
A61F 606

424501

A method for preparing a pharmaceutical microdispersion exhibiting enhanced bioavailability, including the steps of providing a thermodynamically stable pharmaceutical composition comprising at least one lipophilic pharmaceutical agent incorporated in a physiologically acceptable liquid carrier, the liquid carrier comprising one or more lipophilic solvents such as fluorochemicals and preferably at least one nonfluorinated co-solvent, and combining the stable pharmaceutical composition with an amount of at least one miscible diluent sufficient to initiate phase separation of the lipophilic pharmaceutical agent from the pharmaceutical composition wherein a microdispersion of the pharmaceutical composition is formed. Also disclosed are microdisperse pharmaceutical compositions and kits for forming such compositions.